Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,555,507
  • Shares Outstanding, K 51,303
  • Annual Sales, $ 31,940 K
  • Annual Income, $ -109,950 K
  • 60-Month Beta 2.64
  • Price/Sales 49.67
  • Price/Cash Flow N/A
  • Price/Book 7.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.04
  • Number of Estimates 5
  • High Estimate 0.69
  • Low Estimate -0.89
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +107.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.61 +56.50%
on 11/12/19
31.78 -3.43%
on 12/02/19
+10.20 (+49.78%)
since 11/08/19
3-Month
19.29 +59.10%
on 10/10/19
31.78 -3.43%
on 12/02/19
+5.16 (+20.21%)
since 09/10/19
52-Week
17.80 +72.42%
on 12/24/18
31.78 -3.43%
on 12/02/19
+1.70 (+5.86%)
since 12/10/18

Most Recent Stories

More News
Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine...

EDIT : 30.69 (+1.22%)
Don't Judge a Month by its First Day

Don't Judge a Month by its First Day

UAL : 86.51 (-1.26%)
BLDR : 25.67 (-0.10%)
TGT : 125.77 (-0.54%)
KBH : 34.98 (+0.40%)
NAVI : 13.81 (+0.15%)
HPE : 15.84 (-0.31%)
BBY : 82.88 (+0.38%)
DHI : 55.13 (+0.44%)
DKS : 48.18 (+1.24%)
NWL : 18.83 (-1.57%)
SYNA : 56.83 (-0.25%)
VGR : 13.05 (+2.43%)
CRSP : 67.63 (+0.27%)
EDIT : 30.69 (+1.22%)
NTLA : 16.80 (+0.48%)
EDIT January 2020 Options Begin Trading

Investors in Editas Medicine Inc saw new options become available today, for the January 2020 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain...

EDIT : 30.69 (+1.22%)
Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors

Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, announced today that it has appointed Katrine Bosley as Chairman...

EDIT : 30.69 (+1.22%)
GNCA : 2.11 (-1.86%)
Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher

Editas Medicine (EDIT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

EDIT : 30.69 (+1.22%)
ALKS : 21.57 (-0.78%)
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data

Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.

VRTX : 220.27 (+0.41%)
NTLA : 16.80 (+0.48%)
EDIT : 30.69 (+1.22%)
CRSP : 67.63 (+0.27%)
The NASDAQ Needs No Break

The NASDAQ Needs No Break

WYNN : 119.41 (-0.81%)
TAL : 45.27 (-0.44%)
CDAY : 61.98 (+0.37%)
ETSY : 40.51 (-1.58%)
MCD : 194.95 (+0.14%)
JCI : 42.09 (+0.21%)
FTNT : 103.55 (-0.29%)
URI : 153.78 (-1.33%)
SID : 3.17 (+0.96%)
ENTG : 47.41 (+1.33%)
LDOS : 89.64 (-0.51%)
MFC : 19.27 (+0.31%)
ROST : 114.95 (-0.10%)
SSW : 13.77 (+2.38%)
CRSP : 67.63 (+0.27%)
NTLA : 16.80 (+0.48%)
EDIT : 30.69 (+1.22%)
Genome Editing/Genome Engineering Market Analysis Along With Research Report 2019 to 2025

The Global Genome Editing/Genome Engineering Market research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The market Report...

EDIT : 30.69 (+1.22%)
SGMO : 9.06 (-12.17%)
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal

Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.

AGN : 185.61 (+0.18%)
CELG : 108.24 (+0.10%)
EDIT : 30.69 (+1.22%)
CRSP : 67.63 (+0.27%)
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 9.59% and -6.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

EDIT : 30.69 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade EDIT with:

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 31.75
1st Resistance Point 31.22
Last Price 30.69
1st Support Level 30.26
2nd Support Level 29.83

See More

52-Week High 31.78
Last Price 30.69
Fibonacci 61.8% 26.44
Fibonacci 50% 24.79
Fibonacci 38.2% 23.14
52-Week Low 17.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar